Nanogen on Road to Entering Clinical Diagnostics Market, President Says | GenomeWeb

NEW YORK, May 18 - Nanogen is gearing up to launch its first clinical diagnostic products and to see its revenues from product sales increase substantially this year, Kieran Gallahue, the company's president said Friday.

We are accelerating the march to clinical diagnostics," Gallahue told GenomeWeb. "Right now we're selling to clinical researchers, then the next stage is to sell to clinical labs and then to various sized hospitals."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.